|
|||||
|
|
| Rituximab in Combination with CHOP, an Effective and Well-tolerated Salvage Regimen for Diffuse Large B-Cell Lymphoma | |
| 引用本文： | Yong Guan Zhenxia Lu Butong Sun Lintao Bi Pengyu Zhang. Rituximab in Combination with CHOP, an Effective and Well-tolerated Salvage Regimen for Diffuse Large B-Cell Lymphoma[J]. 中国肿瘤临床(英文版), 2007, 4(4): 264-267. DOI: 10.1007/s11805-007-0264-8 |
| 作者姓名： | Yong Guan Zhenxia Lu Butong Sun Lintao Bi Pengyu Zhang |
| 作者单位： | [1]Department of Hematology and Oncology, China-Japan Union Hospital, Changchun 130033, China. [2]Department of Hematology and Oncology, China-Japan Union Hospital, Changchun 130033, China [3]Clinical Laboratory, rianjin Medical University Cancer Institute ＆ Hospital, Tianjin 300060, China. |
| 摘 要： | OBJECTIVE To evaluate the clinical effect of the R-CHOP regimen (rituximab in combination with cyclophosphamide, epirubicin, vincristine and prednisone) in treating refractory or relapsed diffuse large B-cell lymphoma (DLBCL), as a salvage therapy for DLBCL. METHODS Eighteen patients with refractory or relapsed DLBCL who were treated with the R-CHOP regimen from 2001 to 2006 in hospitals in Jilin Province were analyzed retrospectively. The response rate, change of serum lactate dehydrogenase (LDH), time to progression (TTP) and toxicity were observed. RESULTS The R-CHOP regimen can achieve a higher response rate, decrease serum LDH to a larger extent and obtain longer TTP than a con- ventional secondary regimen. The main adverse effects were similar to con- ventional chemotherapy. CONCLUSION The R-CHOP regimen is one of the most effective sec- ondary therapies for DLBCL. |
| 关 键 词： | B细胞淋巴瘤 肿瘤扩散 治疗 诊断 |
| 收稿时间： | 2007-03-25 |
| 修稿时间： | 2007-03-25 |
Rituximab in combination with CHOP, an effective and well-tolerated salvage regimen for diffuse large B-cell lymphoma |
|
| Yong Guan, Zhenxia Lu, Butong Sun, Lintao Bi and Pengyu Zhang. Rituximab in combination with CHOP, an effective and well-tolerated salvage regimen for diffuse large B-cell lymphoma[J]. Chinese Journal of Clinical Oncology, 2007, 4(4): 264-267. DOI: 10.1007/s11805-007-0264-8 | |
| Authors: | Yong Guan Zhenxia Lu Butong Sun Lintao Bi Pengyu Zhang |
| Affiliation: | (1) Department of Hematology and Oncology, China-Japan Union Hospital, Changchun, 130033, China;(2) Clinical Laboratory, Tianjin Medical University Cancer Institute & Hospital, Tianjin, 300060, China;(3) Department of Radiotherapy, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China |
| Abstract: | OBJECTIVE To evaluate the clinical effect of the R-CHOP regimen (rituximab in combination with cyclophosphamide, epirubicin, vincristine and prednisone) in treating refractory or relapsed diffuse large B-cell lymphoma (DLBCL), as a salvage therapy for DLBCL. METHODS Eighteen patients with refractory or relapsed DLBCL who were treated with the R-CHOP regimen from 2001 to 2006 in hospitals in Jilin Province were analyzed retrospectively. The response rate, change of serum lactate dehydrogenase (LDH), time to progression (TTP) and toxicity were observed. RESULTS The R-CHOP regimen can achieve a higher response rate, decrease serum LDH to a larger extent and obtain longer TTP than a con- ventional secondary regimen. The main adverse effects were similar to con- ventional chemotherapy. CONCLUSION The R-CHOP regimen is one of the most effective sec- ondary therapies for DLBCL. |
| Keywords: | large cell lymphoma diffuse rituximab CHOP regimen. |
| 本文献已被 维普 万方数据 SpringerLink 等数据库收录！ | |